<DOC>
	<DOC>NCT00865397</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily Levemir® as initiation of insulin therapy in Hungary.</brief_summary>
	<brief_title>Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Patient with type 2 diabetes inadequately controlled by OAD therapy based on the discretion of individual physician Patient willing to sign informed consent Particular attention should be paid to age limits, indications and contraindications and the drug interactions that are listed within the product labels Subjects with diagnosed type 1 diabetes mellitus Subjects who are unlikely to comply with observational plan, (e.g., uncooperative attitude, inability to return for further visits) Subjects with hypersensitivity to Levemir® or to any of the ingredients Women of childbearing potential, who are pregnant, breastfeeding or intend to become pregnant within next 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>